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Hexachlorobenzene (HCB) is a widespread
environmental pollutant previously used as a
fungicide for seed treatment (1). Currently,
its main sources are impurities present in
other chlorinated pesticides and by-products
ofseveral industrial emissions, notably in the
chlorinated solvent industry through inap-
propriate manufacturing or waste disposal
(2. HCB is ahighlylipophilic chemical that
is frequently found in food and accumulates
in human tissues after ingestion (3,4).
Porphyria is the major potential toxic mani-
festation of this chemical, both in experi-
mental animals and in humans. A porphyria
outbreak has been reported involving more
than 3,000 people who had consumed food
contaminated by HCB during the late 1950s
in Turkey (5). HCB is also a potent carcino-
gen in rodents (6). No information on can-
cer incidence among the Turkish patients is
currently available, but an excess risk for
soft-tissue sarcoma and thyroid cancer has
been found in a population exposed to air-
borne organochlorine mixtures with a high
HCB content (7). Adverse reproductive
effects induced by HCB have also been
reported (8).
Little is known about the metabolism of
HCB in humans despite several complete
rodent studies. Various phenolic deriva-
tives, notably pentachlorophenol (PCP),
tetrachloro-1,4-hydroquinone, and diverse
tetra- and triclorophenols have been iden-
tified in the excreta of rats dosed with
HCB (9). The presence ofPCP in human
urine has been reported in several studies
(10). Because HCB is ubiquitous in
human tissues, some authors have hypoth-
esized that most ofthe PCP found in urine
may arise from the metabolism of the
accumulated HCB (11). PCP, however,
has been widely used as a wood preservant
and is also common in some foods. Thus
the potential direct ingestion of PCP
through diet may hamper the possible cor-
respondence between this polar compound
and HCB.
Another major metabolic pathway
observed in rodents is the conjugation of
HCB with glutathione (12). The glu-
tathione conjugate is further metabolized
by cleavage of the glycine and glutamate
residues to become pentachlorophenyl-N-
acetyl-L-cysteine. Part of the mercapturate
is eliminated unchanged via urine (13,14)
and part may be further metabolized by
cleavage ofthe C-S bond to produce pen-
tachlorobenzenethiol (PCBT), pen-
tachlorothioanisol, tetrachloro-1,4-ben-
zenedithiol, tetrachlorobenzenethiol, pen-
tachlorobenzene, and other minor metabo-
lites (15). A summary of the main HCB
biotransformation pathways in rodents is
shown in Figure 1.
In a previous study of human urine
from a general population, a sulfur metabo-
lite was identified that yielded PCBT after
alkaline hydrolysis (16). However, the rela-
tive importance of this metabolic pathway
for HCB kinetics and disposition, com-
pared to the hydroxylation and formation
ofphenolic derivatives, remained unknown.
Likewise, the significance of the different
metabolites on the mechanism of action
and toxicity of HCB also remains to be
clarified.
A cross-sectional research project on the
health effects of HCB is being carried out
in Flix (Tarragona, Catalonia, Spain), a
rural village of 5,000 inhabitants located
near an organochlorine compound factory
where high airborne HCB exposure has reg-
ularly occurred during approximately the
last four decades (7). This project has also
been used to obtain insight into human
HCB metabolism. Thus, the HCB metabo-
lites in urine samples collected over 24 hr
(24-hr urine samples) of 100 individuals
from this population have been identified,
quantified, and correlated with HCB con-
centration in sera. The significant aspects of
the resulting database for HCB metabolism
in humans are described below.
Materials and Methods
Population ofstudy. A total of615 subjects
ofthe general population (332 selected ran-
domly and 283 volunteers) provided blood
samples and 24-hr urine for the cross-sec-
tional study. Previous written consent for
inclusion in the study was obtained in all
cases. A questionnaire that included
inquiries about residence, occupation,
lifestyle, and medical history was adminis-
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tered. Organochlorine levels in serum were
analyzed in all the 615 participants. A sub-
set of92 subjects ofboth sexes was selected
at random for analysis ofHCB metabolites
in urine. Eight additional 24-hr urine sam-
ples corresponding to the subjects with the
four lowest and the four highest serum
HCB concentrations were also included in
the study. Urine samples were stored at
-70° C until analysis.
Analysis oforganochlorines in serum.
Organochlorine compounds in sera were
analyzed in the Department of
Environmental Chemistry (CID-CSIC).
Two-milliliter aliquots were spiked with an
internal standard of 1,2,4,5-tetrabro-
mobenzene (vortex stirring for 30/sec at
2,000 rpm). n-Hexane (3 ml) was added,
followed by 2 ml concentrated sulfuric
acid. After reaction, the mixture was stirred
for 30 sec and the supernatant n-hexane
phase was separated. The remaining sulfu-
ric acid solution was reextracted two times
with 2 ml n-hexane (stirring 30 sec). The
combined n-hexane extracts (7 ml) were
additionally cleaned with 2 ml sulfuric acid
(stirring 30 sec). Then the n-hexane phase
was separated and concentrated under a
nitrogen stream to 500 pl.
The analyses were performed with a
Hewlett-Packard model 5890 gas chro-
matograph (Hewlett Packard, Palo Alto,
CA) equipped with an automatic injector
and an electron capture detector. Acolumn
of30 m x 0.25 mm inner diameter coated
with DB-5 was used (film thickness 0.25
pm). The temperature was held at 800C
for 1 min and then programmed to 3000C
at 6°C/min, retaining the final temperature
for 10 min. The injector and detector tem-
peratures were 270 and 310°C, respective-
ly. The injector was set in the splitless
mode (solvent, iso-octane; hot needle tech-
nique), keeping the split valve closed for 35
sec. Helium was the carrier gas (50
cm/sec), and nitrogen was used as make-up
gas (60 ml/min).
Thestructural identification ofHCB was
confirmed by analysis ofselected samples by
gas chromatography-mass spectrometry (GS-
MS) in the chemical ionization-negative ion
recording mode (NICI). AVarian Star 3400
(Walnut Creek, CA) coupled to a Finningan
Mat INCOS XL (SanJose, CA) was used for
the analyses. The chromatographic condi-
tions were the same as described above. A
DB-5 column was used. The transfer line
and ion source temperatures were 300 and
1200C, respectively. The reagent gas was
methane. Data were acquired by scanning
from 50 to 500 mass units as 1 sec/decade.
Quantitation was performed by external
standard. Standard curves for several linear
concentration ranges of HCB (0.93-9.3,
Figure 1. Main biotransformation pathways of hexachlorobenzene (HCB) in rodents and main metabolites
found in urine and feces. Abbreviations: PCP, pentachlorophenol; GSH, reduced glutathione; PCBT, pen-
tachlorobenzenethiol; S-PCP-NAC, pentachlorophenyl-N-acetyl-L-cysteine.
9.3-150, and 150-820 ng/ml), 0-hexa-
chlorocyclohexane (,-HCH; 1.75-15.5 and
15.5-1,550 ng/ml), 1,1-dichloro-2,2-bis (p-
chlorophenyl)ethylene (p,p'-DDE; 1.5-13
and 13-130 ng/m), and other organochlo-
rine compounds were performed. The con-
centrations were calculated by interpolation
on the linear curve corresponding to each
compound. In the compounds eluting near
HCB, these concentrations were corrected
for recovery calculated from the internal
standard. The samples were diluted in n-
hexane in cases of concentrations higher
than the linear range. Polychlorinated
biphenyls (PCBs) were calculated by sum-
mation ofthe individual congeners 28, 52,
101, 118, 153, 138, and 180. Standard
curves were determined for each congener.
Detection limits were 0.2, 1.1, 0.7, and 0.05
ng/ml for HCB, f-HCH, p,p'-DDE, and
PCBs, respectively.
Analysis ofHCB metabolites in urine.
Urinary metabolites ofHCB were analyzed
at the Toxicology Unit (Hospital Clinic,
Facultat de Medicina). After hydrolysis of
the urine, conjugated pentachlorophenol
and pentachlorophenyl-N-acetyl-L-cysteine
were assessed as PCP and PCBT, respective-
ly (9). After addition of ascorbic acid (20
mg), the urine samples (4 ml) were spiked
with an internal standard (aldrin) and
digested under N2 with 2 ml of2N NaOH
for 3 hr at 700C. This alkaline hydrolysis
yielded free PCP and PCBT. After cooling
and acidification with HCl (pH = 1), the
derivatives were extracted twice with toluene
(5 ml) and the solvent extracts were concen-
trated to 0.5 ml. Diazoethane in diethyl
ether (0.25 ml) was added for derivatization
(30 min in the dark). The excess dia-
zoethane was removed under a nitrogen
stream, the solvent extracts were concentrat-
ed to approximately 0.1 ml, and 2 ml n-
hexane was added. The resulting mixtures
were cleaned up with H2SO4 (17). The
organic phase was separated and concentrat-
ed to approximately 50 pl. The quantifica-
tion of the ethyl derivatives of PCP and
PCBT was performed in a Hewlett Packard
5890 II gas chromatograph (Hewlett
Packard) equipped with a 5% di-
phenyl-95% dimethylpolysiloxane (HP-
ultra 2, 25 m x 0.2 mm inner diameter)
capillarycolumn and a63Ni electron capture
detector. The temperature was held at 600C
for 1 min and then programmed to 2600C
at 5°C/min, retaining the final temperature
for 45 min. Injector and detector tempera-
tures were 280 and 3000C, respectively.
Injection was in the splidess mode. Helium
was the carrier gas and nitrogen was used as
make-up gas. Quantitation ofboth deriva-
tives was performed by internal standard.
Peak area integration was used (Hewlett
Packard 3396A integrator, Hewlett
Packard), and linearity was checked with
standard calibration curves of PCP and
PCBT. The samples with concentrations
higher than the linear range were diluted
with n-hexane and quantified after addition
ofaldrin. Recovery (88-109%) was assayed
with spiked urines. The detection limit for
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both metabolites was 0.15 ng/ml. The iden-
tity ofboth chromatographic peaks was con-
firmed with a Hewlett-Packard 5971A mass
selective detector (Hewlett Packard) by ion
monitoring [selected ion monitoring (SIM)
for ethyl-PCBT, 310 m/z base peak and
308, 312, 281, 246 mlzconfirmation peaks;
for ethyl-PCP, 294 mlz base peak and 292,
296, 265 m/z confirmation peaks]. The
search for other HCB metabolites was per-
formed by full-scan mass spectrometry or by
SIM (tetrachloro-1,4-benzenedithiol), omit-
ting either hydrolysis (search for free PCBT,
tetrachlorobenzenethiols, etc.) or hydrolysis
and derivatization (search for pentachloroth-
ioanisole), and assaying alternative solvent
extraction procedures (ethyl ether) and alter-
native dean-up procedures (C18). Commer-
cial urines containing known PCP concen-
trations (Lyphochek, Biorad) were used as
internal quality control.
Statistical analysis. Because the
organochlorine compound distributions in
serum and urine were skewed to the right,
the natural logarithmic transformation (ln)
was used in the analysis. To perform all the
statistical analyses, the concentrations of
organochlorine compounds below the detec-
tion limit were set at halfthe limit ofdetec-
tion. Multiple linear regression models were
fitted to assess the association between HCB
levels in serum and its urine metabolites
while adjusting for other possibly confound-
ing variables. The potential confounders
examined induded age (in years), body mass
index (kg/mi2), and current alcohol con-
sumption. The possible confounding effects
of other measured organochlorine com-
pounds was also assessed. The regression
models were stratified by sex including an
interaction term. All analyses were performed
in SPSS.PC (SPSS Inc., Chicago, IL).
Results
The study included 100 subjects (46 males
and 54 females) with a mean age of 49.1
years. HCB was detected in all serum sam-
ples with values ranging between 1.1 and
953.0 ng/ml. HCB levels were higher in
males than in females, but the differences
were not statistically significant. Among
the other major organochlorines analyzed,
PCB levels were detected in all samples,
ranging from 0.07 to 48.9 ng/ml. Levels of
P-HCH were detected in all except nine
cases (8 males, 1 female), ranging from 1.1
to 32.6 ng/ml and levels ofp,p'-DDE were
detected in all except three cases (2 males,
and 1 female), ranging from 0.7 to 67.4
ng/ml (Table 1).
PCP was detected in all urines analyzed
with values ranging between 0.58 and 13.9
pg for 24 hr excretion [mean ± standard
deviation, (SD) 2.51 ± 2.05; geometric
Table 1. Age and organochlorine compound levels
in serum ofthe study participants
Male Female
(n=46) (n=54)
Age in years 48.8 ± 18.9 49.2 ± 18.3
(mean ± SD)
Serum (ng/ml)
HCB
Mean (range) 71.82(1.1-953.0) 18.84(3.7-92.3)
Geometric mean 18.7 15.1
,-HCH
Mean (range) 4.11 (1.1-22.7)** 7.08 (1.1-32.6)
Geometric mean 0.95 3.46
p,p'- DDE
Mean (range) 6.74(0.7-67.4) 6.41 (0.7-28.0)
Geometric mean 2.98 3.76
PCBs
Mean (range) 4.49(0.49-48.9)* 2.93(0.07-13.8)
Geometric mean 2.94 2.03
Abbreviations: SD, standard deviation; HCB, hexa-
chlorobenzene; ,B-HCH,0-hexachlorocyclohexane;
DDE, 1,1-dichloro-2,2-bis (p-chlorophenyl) ethylene;
PCBs, polychlorinated biphenyls.
*p<0.05; **p<0.01 for sex differences.
mean, 2.05; Table 2, Fig. 2]. Only one sam-
ple showed a concentration higher than 9
ng/ml, which may be considered a reference
value (upper normal limit) for PCP in urine
according to Wrbitzky et al. (20). PCBT
(the sum ofall metabolites that yield PCBT
after hydrolysis plus free unconjugated
PCBT) was also detected in all urines with
values ranging between 0.17 and 84 pg
eliminated for 24 hr (mean ± SD, 3.47 ±
10.8; geometric mean, 1.39; Table 2, Fig.
2). Because no reference limits exist for this
derivative, the values previously published
for the general population ofBarcelona (16)
were used as baseline normal levels, and the
highest PCBT concentration found in that
survey (4.5 ng/ml) was tentatively used as
upper normal limit. Eight urine samples of
the population under study exceeded the
upper limit according to this criterion.
When hydrolysis was omitted, traces of
free PCBT could also be detected in the
samples with total PCBT >5 ng/ml. Theval-
ues ranged between 3 and 9% with respect
to the total PCBT. Other major HCB
metabolites identified in rodent studies, such
as tetrachlorobenzene, tetrachloro-1,4 ben-
zenedithiol, tetrachloro-1,4 hydroquinone,
pentachlorothioanisole, and pentachloroben-
zene, could not be detected in any urine at a
concentration above 0.2 ng/ml.
The relationship between urinary
metabolites and HCB in serum is depicted
in Figure 3. The shape of the relationship
was not completely linear. At low HCB lev-
els, thevalues ofPCP were higher than those
of PCBT, whereas at high HCB levels,
PCBT was higher than PCP. Hence, the
PCBT/PCP ratio in urine could be related to
HCB in serum. Thus, ln(PCBT/PCP) and
Table 2. Urinary levels (pg eliminated in 24 hr) of
pentachlorophenol (PCP) and pentachloroben-
zenethiol (PCBT) by hexachlorobenzene (HCB)
serum levels and sex
Male Female
PCP (mean ± SD)
All cases (n= 100) 2.52 ± 2.22 2.53 ± 2.00
HCB,<32ng/ml (n= 82) 1.89± 1.07 2.59± 2.03
HCB, >32 ng/ml (n= 18) 4.08 ± 3.35 1.70 ± 0.62
PCBT(mean± SD)
All cases (n= 100) 6.38 ± 16.16* 1.29 ± 0.79
HCB, <32ng/ml (n= 82) 1.35 ± 1.01 1.20 ± 0.65
HCB, >32ng/ml (n= 18) 18.78± 26.93 2.39± 1.62
SD, standard deviation.
*p<0.01 for sex differences.
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Figure 2. Frequency distribution of pentachlorophe-
nol (PCP) and pentachlorobenzenethiol (PCBT) elim-
inated in urine collected over24 hr.
ln(HCB) were linearly correlated. The
PCBT/PCP ratios were lower and higher
than unit for HCB concentrations below
and above 32 ng/ml, respectively. Table 2
shows the average levels ofmetabolites strati-
fiedbysex and HCB levels.
The results of multiple linear regresion
analysis are shown in Table 3. An increase
of1 ng/ml HCB in serum led to statistically
significant increases ofPCBT urine in both
males and females. The association was
stronger in males than in females (p<0.05
for interaction) when considering all the
individuals, as well as when only assessing
individuals with low levels of HCB (p<O.1
for interaction) We could not assess sex-
related differences in the association at high
levels of HCB given the small number of
women in that group. The association with
PCBT in males did not substantially
change at lowand high HCB levels.
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Table 3. Change (pg/urine collected in 24 hr) and
95% Cl of pentachlorobenzenethiol (PCBT) and
pentachlorophenol (PCP) for each increase of 1
ng/ml of hexachlorobenzene (HCB) in sera for all
individuals and stratified by HCB levels
Male Female
All individuals
PCBT 2.12(1.82-2.44)* 0.67(0.33-1.09)*
PCP 0.63(0.34-0.95)* -0.08 (-0.51-1.23)
HCB <32 ng/ml
PCBT 1.95(1.41-2.58)* 0.79(0.33-1.39)*
PCP 0.54(-0.15-2.27) 0.20 (-0.18-2.80)
HCB >32 ng/ml
PCBT 2.09(1.15-3.33)* a
PCP 0.77 (0.45-1.16)* a
an<5.
*p<0.01
10 100 1,000
HCB (ng/ml)
0a 0L CL
C.)
0.1 E
1 10 100 1,000
HCB (ng/ml)
Figure 3. Correlation plots of pentachlorophenol (PCP) and pentachlorobenzenethiol (PCBT) eliminated in
urine collected over 24 hr versus hexachlorobenzene (HCB) concentration in serum.
The association between HCB and PCP
was less consistent (12 was 0.78 in the regre-
sion model with PCBT, and it was reduced
to 0.19 in the regression model with PCP).
The association only occurred in males and
at high levels ofHCB. The inclusion of age,
body mass index, and alcohol consumption
in the models did not confound the above
results, and neither did the inclusion ofother
organochlorines (HCH,p,p'-DDE, PCBs).
Discussion
The serum HCB values found in the sub-
jects from Flix are significandy higher than
those found in other European and U.S.
studies (18,151), including those found in a
recent survey ofthe population ofBarcelona
(4). Other ubiquitous organochlorines such
asp,p'-DDE and [-HCH were not particu-
larly high compared to these other reports.
This indicates that in Flix there is a particu-
lar exposure to HCB but not ageneral expo-
sure to organochlorines.
These elevated serum HCB concentra-
tions were not reflected, however, in notable
increases in PCP excretion via urine.
Concentrations above 9 ng/ml were found
only in one sample. These observations con-
tradict previous statements (11) and show
that HCB hydroxylation leading to the for-
mation of PCP in humans is very small in
comparison with HCB accumulation.
Moreover, some PCP in urine may arise
from PCP present in food that is absorbed
and eliminated unchanged or after conjuga-
tion with glucuronic acid. The PCBT/PCP
ratio in the subjects with low HCB levels
and the weak association between PCP and
HCB reinforces this possibility.
The elimination of HCB as a sulfur
metabolite was higher than the elimination
as PCP in those individuals with higher
internal dose of HCB (HCB in serum >32
ng ml). These observations show that the
conjugation ofHCB with glutathione, lead-
ing to the formation ofhydrosoluble sulfur
metabolites, is a quantitatively more impor-
tant biotransformation pathway than the
hydroxylation and formation of phenolic
metabolites. This is evident in the individuals
with higher HCB levels for which the ratio
PCBT/PCP (>1) is not as confounded by
exogenous PCP as it may be in those with
low HCB levels. The urinary metabolite that
yields PCBT after alkaline hydrolysis is most
probably pentachlorophenyl-N-acetyl-L-cys-
teine, although the presence of other closely
related conjugates cannot be totallyexcluded.
These results confirm an earlier report that
showed the presence of a sulfur derivative in
human urine assessed as PCBT (16). Urinary
PCBT could also arise from ingestion and
metabolism of the fungicide pentachloroni-
trobenzene (quintozene), but no exposure to
that compound has been reported for the
population under study. Moreover, the asso-
ciation between PCBT and HCB dearly sug-
gests that most of the PCBT in urine arises
from the metabolism ofHCB.
When hydrolysis was omitted, free
PCBT could be detected in some urines.
This suggests that a minor part ofthe mer-
capturate may undergo in vivo cleavage of
the C-S bond to yield free PCBT. This
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pathway has been clearly documented in
rodents (12,15), but the possibility ofsome
degree of bacterial mediated hydrolysis
during urine collection or spontaneous
hydrolysis during acidification cannot be
ruled out.
The very strong association between
PCBT in urine and HCB in serum is strik-
ing and suggests a biotransformation path-
way with small interindividual variations
and scarcely affected by modifiers ofhepat-
ic enzymatic activity. These results are
enhanced by the fact that the two parame-
ters (HCB in serum, PCBT in urine) were
analyzed and quantified by two indepen-
dent laboratories. The addition of eight
subjects with extreme values to the analysis
of the randomly selected individuals did
not modify any ofthe findings.
The excretion ofthe sulfur conjugate in
urine showed a sex-related difference: males
eliminated more PCBT than females. This
could reflect some sex-related differences
including perhaps a more efficient HCB
metabolism in men. The confirmation of
this finding requires further investigation,
which is difficult to carry out in humans,
but the results are in accordance with some
studies made on populations exposed to
background HCB, which have found high-
er HCB body burdens in women (22,23).
Several studies in rats have shown sex-relat-
ed differences in HCB metabolism together
with higher susceptibility of females to
HCB-induced porphyria (24,25), but a
mechanistic link between both has not been
elucidated. Another sex-related difference
has been shown in rats, with females elimi-
nating pentachlorophenyl-N-acetyl-L-cys-
teine in urine with a higher efficiency than
males (13,14). The difference appears after
rats are treated with either HCB or pen-
tachloronitrobenzene, but it also appears
after dosing the animals directly with pen-
tachlorophenyl-N-acetyl-L-cysteine. As a
consequence, the differences do not origi-
nate in a different rate of formation of the
final cysteine derivative, but in a sex-depen-
dent renal secretion mechanism particularly
developed in female rats (13). The existence
of a similar mechanism in species other
than rats, however, has been not reported.
The relationship between HCB metab-
olism and toxicity is still not clear.
Cytochrome P450-mediated oxidative
metabolism has been implicated in several
toxic effects of HCB, notably hypothy-
roidism (26) and porphyria (27,28) in
rodent chronic studies.
These results show a low PCP urinary
output, confirming the poor efficiency of
HCB oxidative metabolism in humans.
Taking into account the accumulation
kinetics of HCB in adipose tissue and the
high adipose:blood concentration ratios
reported (4,21), it is evident that only avery
small fraction ofHCB body burden is being
metabolized to phenolic derivatives and
eliminated via urine. This is compatible
with a possibly important role ofthis minor
oxidative metabolism in HCB toxicity, but
conclusive mechanistic studies are still lack-
ing. Differently, the formation of the cys-
teine conjugate is probably a detoxication
pathway, and its efficiency in individuals
with high HCB serum levels indicates a
probable main protective role against HCB
toxicity. The association found between
serum HCB and urinary metabolites shows,
for the first time in humans, that the sulfur
derivative assessed as PCBT is a good uri-
nary marker ofHCB internal dose and glu-
tathione-mediated metabolism. The analysis
of feces in the same population is under
study and will eventually provide a more
complete approach to the kinetics of HCB
in humans.
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